World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
98
Citations
38720
World Ranking
452
National Ranking
209

Medicine

D-Index
100
Citations
40041
World Ranking
8236
National Ranking
4268

Overview

Keith S. Kaye is affiliated with Rutgers, The State University of New Jersey in the United States. Their research spans a broad range of topics primarily within medicine and biochemistry, genetics, and molecular biology. The scientific work focuses notably on epidemiology, molecular medicine, applied microbiology and biotechnology, pharmacology, and infectious diseases.

The main areas of research include antibiotic resistance in bacteria, antibiotic use and resistance, antibiotics pharmacokinetics and efficacy, urinary tract infections management, bacterial identification and susceptibility testing, pneumonia and respiratory infections, and nosocomial infections in intensive care units (ICU).

Keith S. Kaye has published extensively, with several recent papers appearing in high-impact journals. Notable publications include:

  • "Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial" (2020), The Lancet Infectious Diseases
  • "Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study" (2020), The Lancet Infectious Diseases
  • "Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study" (2021), The Lancet Infectious Diseases
  • "Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study" (2023), The Lancet Microbe
  • "Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)" (2023), The Lancet Infectious Diseases

Frequent coauthors in Keith S. Kaye's publications include:

  • Jason M. Pogue
  • Robert A. Bonomo
  • Sorabh Dhar
  • David van Duin
  • Chetan Jinadatha

The most common venues where Keith S. Kaye publishes are:

  • Open Forum Infectious Diseases
  • Clinical Infectious Diseases
  • Infection Control and Hospital Epidemiology
  • UNC Libraries
  • Antimicrobial Stewardship & Healthcare Epidemiology

Keith S. Kaye's research contributes to understanding and addressing critical challenges related to antibiotic resistance, treatment efficacy, and clinical outcomes for serious bacterial infections, especially in hospital and ICU settings.

Best Publications

  • Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.

    N. Deborah Friedman;Keith S. Kaye;Jason E. Stout;Sarah A. McGarry

  • Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update

    Deverick J. Anderson;Kelly Podgorny;Sandra I. Berríos-Torres;Dale W. Bratzler

  • Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

    John J. Engemann;Yehuda Carmeli;Sara E. Cosgrove;Vance G. Fowler

  • The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges.

    Sara E. Cosgrove;Youlin Qi;Keith S. Kaye;Stephan Harbarth

  • International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

    Brian T. Tsuji;Jason M. Pogue;Alexandre P. Zavascki;Mical Paul;Mical Paul

  • Diabetes and Risk of Surgical Site Infection: A Systematic Review and Meta-analysis.

    Emily T. Martin;Keith S. Kaye;Caitlin Knott;Huong Nguyen

  • Strategies to Prevent Surgical Site Infections in Acute Care Hospitals

    Deverick J. Anderson;Keith S. Kaye;David Classen;Kathleen M. Arias

  • Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

    David Van Duin;Judith J. Lok;Michelle Earley;Eric Cober

  • Strategies to Prevent Central Line-Associated Bloodstream Infections in Acute Care Hospitals

    Jonas Marschall;Leonard A Mermel;David Classen;Kathleen M Arias

  • Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae

    Mitchell J. Schwaber;Shiri Navon-Venezia;Keith S. Kaye;Ronen Ben-Ami

  • A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates

    Deborah S. Yokoe;Deverick J. Anderson;Sean M. Berenholtz;David P. Calfee

  • Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

    Haley J. Morrill;Jason M. Pogue;Keith S. Kaye;Kerry L. LaPlante

  • Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes

    David van Duin;Keith S. Kaye;Elizabeth A. Neuner;Robert A. Bonomo

  • Strategies to prevent ventilator-associated pneumonia in acute care hospitals.

    Susan E. Coffin;Michael Klompas;David Classen;Kathleen M. Arias

  • Strategies to Prevent Catheter‐Associated Urinary Tract Infections in Acute Care Hospitals

    Evelyn Lo;Lindsay Nicolle;David Classen;Kathleen M. Arias

  • Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

    Richard G. Wunderink;Yuko Matsunaga;Mari Ariyasu;Philippe Clevenbergh

  • RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

    Johann Motsch;Cláudia Murta de Oliveira;Viktor Stus;Iftihar Köksal

  • Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

    Richard G. Wunderink;Evangelos J. Giamarellos-Bourboulis;Galia Rahav;Amy J. Mathers

  • Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management

    Keith S. Kaye;Jason M. Pogue

  • Health and Economic Outcomes of the Emergence of Third-Generation Cephalosporin Resistance in Enterobacter Species

    Sara E. Cosgrove;Keith S. Kaye;George M. Eliopoulous;Yehuda Carmeli;Yehuda Carmeli

  • Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system

    Jason M. Pogue;Jason M. Pogue;Jiha Lee;Dror Marchaim;Victoria Yee

  • Rocky mountain spotted fever.

    Daniel J Sexton;Keith S Kaye

Frequent Co-Authors

Jason M. Pogue
Jason M. Pogue University of Michigan–Ann Arbor
Michael J. Rybak
Michael J. Rybak Wayne State University
Daniel J. Sexton
Daniel J. Sexton Duke University
Emily T. Martin
Emily T. Martin University of Michigan–Ann Arbor
Federico Perez
Federico Perez Case Western Reserve University
Vance G. Fowler
Vance G. Fowler Duke University
Robert A. Bonomo
Robert A. Bonomo Case Western Reserve University
Yehuda Carmeli
Yehuda Carmeli Tel Aviv University
Kenneth E. Schmader
Kenneth E. Schmader Duke University
Sandra S. Richter
Sandra S. Richter Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can open doors to diverse career pathways beyond traditional microbiology roles. For example, earning online degrees for felons provides accessible education options for those overcoming past challenges, making higher education more inclusive.

If you are interested in healthcare with a focus on holistic approaches, becoming a functional medicine nurse practitioner could be an exciting pathway. This role combines patient care with an emphasis on integrative health, blending scientific knowledge with patient-centered treatment.

For those who prefer a career in healthcare administration, pursuing certification as a certified professional coder can lead to vital positions managing medical coding and billing. Complementing this, roles like a health information manager salary reflect the growing demand for professionals who oversee medical records and health data management.

These pathways highlight interdisciplinary opportunities linked to microbiology education, broadening your career potential in the healthcare and scientific sectors. Choosing the right degree or certification is essential for aligning your skills with future job markets.

Best Scientists Citing Keith S. Kaye

Trending Scientists

Recently Published Articles